1. Home
  2. RGA vs UTHR Comparison

RGA vs UTHR Comparison

Compare RGA & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGA
  • UTHR
  • Stock Information
  • Founded
  • RGA 1973
  • UTHR 1996
  • Country
  • RGA United States
  • UTHR United States
  • Employees
  • RGA N/A
  • UTHR N/A
  • Industry
  • RGA Life Insurance
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • RGA Finance
  • UTHR Health Care
  • Exchange
  • RGA Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • RGA 12.4B
  • UTHR 20.7B
  • IPO Year
  • RGA 1993
  • UTHR 1999
  • Fundamental
  • Price
  • RGA $189.59
  • UTHR $446.81
  • Analyst Decision
  • RGA Buy
  • UTHR Buy
  • Analyst Count
  • RGA 10
  • UTHR 12
  • Target Price
  • RGA $239.89
  • UTHR $495.08
  • AVG Volume (30 Days)
  • RGA 442.4K
  • UTHR 591.7K
  • Earning Date
  • RGA 10-30-2025
  • UTHR 10-29-2025
  • Dividend Yield
  • RGA 1.96%
  • UTHR N/A
  • EPS Growth
  • RGA 18.96
  • UTHR 16.08
  • EPS
  • RGA 12.98
  • UTHR 26.38
  • Revenue
  • RGA $22,304,000,000.00
  • UTHR $3,128,400,000.00
  • Revenue This Year
  • RGA $7.57
  • UTHR $13.68
  • Revenue Next Year
  • RGA $10.61
  • UTHR $5.63
  • P/E Ratio
  • RGA $14.61
  • UTHR $17.03
  • Revenue Growth
  • RGA 1.97
  • UTHR 13.50
  • 52 Week Low
  • RGA $159.25
  • UTHR $266.98
  • 52 Week High
  • RGA $233.81
  • UTHR $479.50
  • Technical
  • Relative Strength Index (RSI)
  • RGA 50.57
  • UTHR 56.88
  • Support Level
  • RGA $178.21
  • UTHR $430.02
  • Resistance Level
  • RGA $192.21
  • UTHR $456.41
  • Average True Range (ATR)
  • RGA 4.59
  • UTHR 14.19
  • MACD
  • RGA 0.18
  • UTHR 0.19
  • Stochastic Oscillator
  • RGA 78.70
  • UTHR 51.88

About RGA Reinsurance Group of America Incorporated

Reinsurance Group of America Inc is an insurance holding company with operations in the United States, Latin America, Canada, Europe, Africa, Asia, and Australia. The core products and services include life reinsurance, living benefits reinsurance, group reinsurance, health reinsurance, financial solutions, facultative underwriting, and product development. The company's operations are divided into traditional and financial solution businesses.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: